ALTITUDE: A Phase 2 Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3

Hepion Pharmaceuticals, Inc. (Industry)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

This is a randomized, open-label, parallel-dosing, multi-center study to evaluate the safety and efficacy of rencofilstat as evidenced by assessing changes in the HepQuant Shunt Disease Severity Index Score (DSI), safety labs, and clinical events in adult NASH subjects with compensated Fibrosis stage F3. Antifibrotic biomarker activity will be evaluated on an exploratory basis.

Condition or Disease Intervention/Treatment Phase
  • Drug: rencofilstat, 75 mg
  • Drug: rencofilstat, 150mg
  • Drug: rencofilstat, 225 mg
Phase 2

Detailed Description

This study consists of 3 phases: (i) Screening and Randomization; (ii) treatment; and (iii) follow up. During Screening, each subject will provide informed consent prior to starting any study specific procedures. The randomization of the NASH F3 subjects will be performed in a 1:1:1 ratio between rencofilstat 75 mg, rencofilstat 150 mg, and rencofilstat 225 mg. During the treatment period, randomized subjects will be provided the treatment and assessments to monitor safety, tolerability and efficacy. All subjects will receive study drug in the morning. Prior to dosing, subjects can have a light breakfast, avoiding high fat meals. In the follow up phase, investigational product (IP) will be discontinued followed by 14 days of safety follow-up.

Study Design

Study Type:
Anticipated Enrollment :
60 participants
Intervention Model:
Parallel Assignment
None (Open Label)
Primary Purpose:
Official Title:
ALTITUDE NASH: A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis Stage 3 Fibrosis
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cohort A: rencofilstat 75 mg

1 rencofilstat 75 mg softgel capsule, 75 mg daily dose, QD 120 days

Drug: rencofilstat, 75 mg
1 softgel capsule

Experimental: Cohort B: rencofilstat 150 mg

2 rencofilstat 75 mg softgel capsules, 150 mg daily dose, QD 120 days

Drug: rencofilstat, 150mg
2 softgel capsules

Experimental: Cohort C: rencofilstat 225 mg

3 rencofilstat 75 mg softgel capsules, 225 mg daily dose, QD 120 days

Drug: rencofilstat, 225 mg
3 softgel capsules

Outcome Measures

Primary Outcome Measures

  1. Change from baseline in DSI score of subjects taking rencofilstat (75 mg, 150 mg, 225 mg), determined using HepQuant SHUNT Test, on Day 60, and Day 120. [120 Days]

    Primary Efficacy Endpoint

  2. The percent of subjects taking rencofilstat (75 mg, 150 mg, 225 mg) that have experienced treatment-emergent adverse events, serious adverse events, adverse events of special interest, physical and laboratory abnormalities. [120 Days]

    Primary Safety Endpoint

Eligibility Criteria


Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  1. Male or female between 18 and 75 years of age (inclusive).

  2. BMI above 25.0 kg/m2

  3. Biopsy confirmed NASH with histologic liver fibrosis stage 3 as defined by the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) scoring of liver fibrosis based on available historical biopsy report if the following are met:

  1. Historical biopsy was obtained no more than 6 months (180 ± 5 days) prior to the first day of Screening. ii. No new therapeutic intervention for NASH of at least 2 or more weeks was made during the preceding 3-month (90-day) period (e.g., vitamin E ≥ 400 IU/day, pioglitazone, or incretins [e.g., liraglutide, semaglutide]). Subjects may be treated with vitamin E or pioglitazone as long as such subjects are maintained on a stable dose for 3 months prior to randomization, and the dose should be held constant during the trial.
  1. Subjects without historical biopsy will be eligible for inclusion if their AGILE 3+ score using the FibroScan Diagnostic App is ≥0.53. The AGILE 3+ score is composed of: FibroScan fibrosis score, laboratory values (AST, ALT, Platelets), and clinical parameters (Age, Sex, Diabetes status) to calculate the AGILE 3+ score.
Exclusion Criteria:
  1. Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus antibodies (HIVAb). If HCVAb test is positive, then an HCV-RNA test will be performed. If this test is negative, the subject is allowed to participate in the study, as long as the subject meets all other inclusion criteria and has never been treated for HCV or was treated >2 years ago and achieved a sustained virologic response at that time.

  2. Subjects with symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection identified during the screening period.

  3. At screening, subjects with uncontrolled hypertension (either treated or untreated) defined as a systolic blood pressure >160mmHg or a diastolic blood pressure of


  1. Subjects on either a non-selective beta blocker or an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) who are unwilling/unable to delay taking their normal dose the morning of HepQuant testing.

  2. Subjects with transaminases >5 x upper limit of normal (ULN).

  3. Subjects with ALP >2 x ULN.

  4. Subjects with total serum bilirubin >1.5 x ULN, unless the subject has Gilbert's Syndrome, in which case the subject can be enrolled provided the direct bilirubin is within 30% of the total bilirubin.

  5. Subjects with a platelet count <140,000/mm3.

  6. Subjects with an INR ≥ 1.3 in the absence of anticoagulants.

  7. Subjects with albumin <3.5 g/dL.

  8. Model for End-Stage Liver Disease (MELD) score >12, unless due to an alternate etiology such as therapeutic anticoagulation or Gilbert's.

  9. An estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] method).

  10. Subjects with hemoglobin A1c (HbA1c) >9.5%.

  11. Other well documented causes of chronic liver disease according to standard diagnostic procedures.

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • Hepion Pharmaceuticals, Inc.


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Hepion Pharmaceuticals, Inc. Identifier:
Other Study ID Numbers:
  • HEPA-CRV431-210
First Posted:
Jul 15, 2022
Last Update Posted:
Jul 15, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 15, 2022